Skip to content
  • About
    • What we do
    • Our history
    • Our team
    • Our committees
    • Our partners
    • About genomics
  • Services
    • What we offer
    • Research we’re supporting
  • Tools & resources
    • Search all tools & resources
    • Research ethics & governance
    • Consent & patient support materials
    • Evaluating genomic research & translation
    • Data governance
    • Access our datasets
    • Data capture & standardisation
    • Data analysis & interpretation
    • Workforce education
    • Our publications
    • Our submissions
  • Our project areas
    • Our project areas
    • Genomic information management
    • Clinical genomic practice
    • Genomic literacy, workforce & training
    • Indigenous genomic priorities
    • Genomic diagnostics
    • Evaluating genomic research & translation
    • Australian health system policy & practice
    • Involvement & engagement
  • News & events
    • News
    • Events
    • Personal stories
    • Search news & events
  • Connect with us
Laughing child leaning back on woman's knee

Australian Genomics’ submissions to MSACs targeted consultation opportunities

Home Our publications Australian Genomics’ submissions to MSACs…

The Medical Services Advisory Committee (MSAC) regularly seeks targeted feedback from Australian Genomics on genetic and genomic-related applications for public funding of medical services and technologies. Australian Genomics develops feedback for submissions by consulting with expert members drawn from its 450-strong network of professionals, to put forward unified, evidence-based submissions.

April 2021

Response to MSAC Application 1658: ‘Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS Olaparib’.

Response to MSAC Application 1658 Consultation Survey

Response to MSAC Application 1660: ‘Diagnostic testing for mesenchymal-epithelial transition (MET) Exon 14 (METex14) skipping alterations in non-small cell lung cancer (NSCLC) to determine Pharmaceutical Benefits Scheme eligibility for tepotinib treatment’.

Response to MSAC Application 1660 Consultation Survey

August 2021

Response to MSAC Application 1669 ‘KRAS G12C variant testing to determine eligibility for PBS subsidized sotorasib second-line therapy in patients with locally advanced or metastatic NSCLC’.

Response to MSAC Application 1669 Consultation Survey

Response to MSAC Application 1671 ‘Carrier screening for severe monogenic disorders’.

Response to MSAC Application 1671 Consultation Survey

November 2021

Response to MSAC Application 1675 ‘Whole Genome Sequencing for the diagnosis of mitochondrial disease’.

Response to MSAC Application 1675 Consultation Survey

Response to MSAC Application 1680 ‘Genetic testing for childhood hearing impairment’.

Response to MSAC Application 1680 Consultation Survey

Response to MSAC Application 1684 ‘Genetic testing for variants associated with haematological malignancies’.

Response to MSAC Application 1684 Consultation Survey

October 2022

Response to MSAC Application 1721: ‘Small gene panel testing for non-small cell lung carcinoma.’

Response to MSAC Application 1721 Consultation Survey

Connect with us

(03) 9936 6345
info@australiangenomics.org.au
50 Flemington Road, Parkville
Victoria 3052 Australia

In the spirit of reconciliation Australian Genomics acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

To stay informed about our work, sign up to our newsletter

Subscribe

Quicklinks

  • Home
  • What we do
  • What we offer
  • Tools & resources
  • Our publications
  • Our project areas
  • Research we’re supporting
  • Our team

Privacy

  • We follow the Australian Privacy Principles
  • General privacy policy
  • Website privacy policies
  • Terms & conditions

Website by Blueboat.